Abstract:
Herein is described a cell density signaling protein and its tissue-specific lipid cofactor. Constructs, compositions and methods for isolation, purification and use of the protein and the tissue-specific lipid cofactor are described.
Abstract:
L'invention se rapporte à de nouveaux composés qui répondent à la formule générale (I): Formula (I), dans laquelle: m = 0, 1 ou 2; R 1 et R 2 = un groupe hydrocarboné, linéaire ou ramifié, en C 6 à C 12 ; R 3 = H, un groupe hydrocarboné, linéaire ou ramifié, en C 1 à C 12 , comprenant éventuellement un ou plusieurs hétéroatomes; un groupe hydrocarboné monocyclique en C 3 à C 8 , comprenant éventuellement un ou plusieurs hétéroatomes, ou un groupe (hétéro)aryle monocyclique; ou bien R 2 et R 3 forment ensemble un groupe -(CH 2 ) n - avec n = de 1 à 4; R 4 = un groupe hydrocarboné, linéaire ou ramifié, en C 2 à C 8 , ou un groupe aromatique monocyclique; R 5 = H ou un groupe hydrocarboné, linéaire ou ramifié, en C 1 à C 12 . L'invention se rapporte également à des procédés de synthèse de ces composés ainsi qu'à l'utilisation desdits composés comme ligands de l'uranium(VI) et, en particulier pour extraire l'uranium(VI) d'une solution aqueuse d'acide phosphorique.
Abstract:
Monomers of formula (I) which include a vinyl group, polymers and articles, such as contact lenses, made therefrom, all of which are biocompatible, are described.
Abstract:
The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SlP receptors.
Abstract:
Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.
Abstract:
Photofunctional materials having vinylphosphonic acid groups, preferably photofunctional materials having chemical structures represented by the general formula (1): (1) (wherein X is a monovalent organic residue; R and R are each independently hydrogen or a monovalent organic residue; M and M are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted silyl, or a cation; R and R , R and X, or R and X may be united to form a ring; and X and R may be replaced with each other). The photofunctional materials are favorably usable as sensitizing dyes for dye-sensitized photoelectric conversion cells and can attain high photoelectric conversion efficiency and strong adsorption to the interface of an inorganic semiconductor.
Abstract translation:具有乙烯基膦酸基团的光功能材料,优选具有由通式(1)表示的化学结构的光官能材料:(1)(其中X是一价有机残基; R 1和R 2各自独立地为氢或一价 有机残基; M 1和M 2各自独立地为氢,取代或未取代的烷基,取代或未取代的芳基,取代或未取代的甲硅烷基或阳离子; R 1和R 2,R 1, 并且X或R 2和X可以结合形成环; X和R 2可以彼此替代)。 光功能材料有利地用作染料敏化光电转换电池的敏化染料,并且可以获得高的光电转换效率和对无机半导体的界面的强吸附。
Abstract:
A process of synthesizing a compound of formula (1) is described. A compound of formula (2) is reacted with diphenylphosphinic chloride to activate the carboxylic acid group, and then reacted with methanesulfonyl chloride to produce a compound of formula (4). Compound (4) is then reacted with a group II metal sulfide source in water to produce a compound of formula (1).
Abstract:
There are provided inter alia novel N-phenyl substituted pyrrole derivativesand theiruse in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.
Abstract:
Die vorliegende Erfindung betrifft eine monosubstituierte Phosphinsäure sowie deren Einsatz als Regler in radikalischen Polymerisationen. Solche Regler führen nicht zur Bildung von schlechtlöslichen Salzen, ferner weisen sich die durch den erfindungsgemässen Regler hergestellten Polymere durch einen einheitlichen Polymerisationsgrad mit einer engen Grössenverteilung aus. Zusätzlich betrifft die Erfindung ein Verfahren zur Herstellung solcher monosubstituierten Phosphinsäuren.
Abstract:
The invention provides compounds useful in inhibiting the activity of a Wip1 protein in a cell as well as prodrugs thereof, related methods of use and compositions which include the aforesaid compounds and prodrugs thereof. The compounds comprise a ring structure having at least five functional groups bonded thereto, wherein each functional group is bonded to a different ring atom, and wherein the at least five functional groups comprise: (a) first (R 1 ) and second (R 3 ) moieties each comprising a phosphate group wherein these first and second moieties are separated by at least one ring atom; (b) first (R 2 ) and second (R 4 ) hydrophobic groups, wherein the first and second hydrophobic groups are separated by at least one ring atom, and wherein the first hydrophobic group is bonded to a ring atom located between the ring atoms to which the first (R 1 ) and second (R 2 ) moieties are bonded; and an amide or carboxylic acid (R 5 ).